| Similar Articles |
|---|
 |
The Motley Fool
August 1, 2008
Brian Lawler |
Holy Moley, CV Therapeutics! With big successes on the regulatory and financial fronts, CV Therapeutics has had a quarter where everything went right.   |
The Motley Fool
February 13, 2007
Brian Lawler |
CVT, We Wait for Thee CV Therapeutics' angina treatment could be set for a big boost. But what investors are getting with CVT today is a specialty pharma that is rapidly burning the cash on its balance sheet. |
The Motley Fool
September 17, 2008
Brian Lawler |
CV Therapeutics Expands Ranexa's Reach CVT announces that it has finally found a European marketing partner for its angina treatment Ranexa. |
The Motley Fool
July 10, 2006
Brian Lawler |
CV Therapeutics Gets Greenlighted A final trial could secure full FDA approval for angina drug Ranexa. Investors, take note. |
The Motley Fool
March 7, 2007
Brian Lawler |
A CV Therapeutics Buying Opportunity? Shares of CV Therapeutics tank after reporting mixed results from a pivotal clinical trial for its lead drug. |
The Motley Fool
November 7, 2007
Brian Lawler |
Turnaround Time for CVT CV Therapeutics announces in its third-quarter financial results that it plans to have a better 2008; its angina drug shows promise for treating diabetics. Investors, take note. |
The Motley Fool
September 26, 2006
Brian Lawler |
CVT's Looming Date With Destiny A pivotal trial for its lead drug, Ranexa, is nearing completion. Investors, take note. |
The Motley Fool
August 1, 2007
Brian Lawler |
CV Therapeutics' Turnaround Quarter Putting a close to a turnaround second quarter, CV Therapeutics announced its financial results recently. It looks like shareholders are in for some good times. |
The Motley Fool
April 17, 2008
Brian Lawler |
CVT's Copacetic Cash Management Drugmaker CV Therapeutics signs away a little portion of its royalty stream from a recently approved drug, in order to get a lot back. |
The Motley Fool
April 14, 2008
Brian Lawler |
A Little Delay Goes Away for CVT CV Therapeutics can move ahead, now that it has won marketing approval for its cardiac stress agent regadenoson. |
The Motley Fool
November 1, 2006
Brian Lawler |
Waiting for CVT's Trial Results The biopharm reported third-quarter 2006 earnings that were mostly as expected. Investors are just awaiting the clinical trial results from the company's large phase 3 Merlin study testing its marketed angina drug, Ranexa. |
The Motley Fool
January 28, 2009
Brian Orelli |
M&A Off the Beaten Path CV Theraputics gets courted. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
BusinessWeek
February 2, 2004
Gene G. Marcial |
CV Investors: Take Heart Lately, CV Therapeutics is bouncing around on rumors of what the Food & Drug Administration might do about Ranexa, CV's angina treatment. One New York fund manager, who asked not to be identified, is buying shares because he expects a takeover bid. |
The Motley Fool
April 4, 2005
Karl Thiel |
CV Therapeutics' Great Resume With biotechs in the doldrums, this investor goes hunting. |
The Motley Fool
July 6, 2007
Brian Lawler |
Medicines Decides Not to Share The Medicines Company reacquires its own drug. Until now, privately held European specialty pharma Nycomed has marketed Angiomax in Europe. Investors, take note. |
The Motley Fool
August 7, 2008
Brian Orelli |
The Next Pharma Acquisition The rate of mergers and acquisitions among drugmakers has reached a feverish pace lately, and doesn't show any signs of slowing down anytime soon. Take a look at some likely candidates. |
The Motley Fool
March 12, 2009
Brian Orelli |
2 Suitors Are Better Than 1 Recent drug company acquisitions prove that competition benefits shareholders. |
The Motley Fool
December 30, 2008
Brian Orelli |
The FDA Needs a Bake Sale Money seems to be at the root of the problem with the FDA right now. It's pretty clear that fees, even though they're up to over $1 million per marketing application, aren't enough to get things done in a timely manner. |
The Motley Fool
December 9, 2008
Brian Orelli |
The FDA Can't See the Forest or the Trees Forest Laboratories and Cypress Bioscience are still waiting for FDA approval, but now they've got more data to prove their point. |
Chemistry World
November 28, 2008
Matt Wilkinson |
EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market. |
Pharmaceutical Executive
June 1, 2014 |
Hopes High as EU Heads Into Leadership Change The principal drug industry associations in Europe launched a call in mid-May for "an integrated European industrial policy for the pharmaceuticals sector." |
